Mobble
Health · Drug development · published 2026-08-18 · via Endpoints News

Amylyx's avexitide hits Phase 3 goal in post-bariatric hypoglycemia

Amylyx Pharmaceuticals announced a successful Phase 3 trial for avexitide, a GLP-1 receptor antagonist, in patients with post-bariatric hypoglycemia. The company, which previously focused on ALS research, is shifting its pipeline toward GLP-1-targeted therapies. Specific efficacy and safety details from the study were not disclosed in the announcement.

Read the full article at Endpoints News →
Related stories
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
AstraZeneca terminates Phase 3 volrustomig study following lung cancer failure · Cancer research
Ivonescimab meets key goal in biliary tract cancer trial, partners report · Cancer research
Bausch + Lomb pushes dry eye therapy to Phase 3 after Phase 2 miss · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia.” Browse more stories.